CHEK2 and cancer: Overall, the six genes that had PVs with prevalences greater than one percent for any patient cohort (ATM, BRCA1, BRCA2, CHEK2, CDKN2A and FANCA) comprise a heterogenous group of genes that reflect the complexity of this cancer.